Sanara MedTech (SMTI) Q1 2026 Earnings Transcript

Sanara MedTech reported strong Q1 2026 results with 19% year-over-year revenue growth to $27.8 million, driven by increased sales of soft tissue repair products CellerateRX and BIASURGE. The company achieved GAAP net profitability with $0.4 million net income ($0.04 per diluted share), improved gross margins to 93%, and paid debt service entirely in cash for the first time. Management maintained full-year 2026 guidance of $116-121 million revenue (13-17% growth) and expects OsStic synthetic bioadhesive product launch in Q1 2027.